Sandoz Inc. v. Amgen Inc.
137 S. Ct. 808, 196 L. Ed. 2d 594, 85 U.S.L.W. 3343, 2017 WL 125661, 2017 U.S. LEXIS 692
CourtSupreme Court of the United States
DecidedJanuary 13, 2017
DocketNo. 15–1039.
StatusPublished
Cited by1 cases
This text of 137 S. Ct. 808 (Sandoz Inc. v. Amgen Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Bluebook
Sandoz Inc. v. Amgen Inc., 137 S. Ct. 808, 196 L. Ed. 2d 594, 85 U.S.L.W. 3343, 2017 WL 125661, 2017 U.S. LEXIS 692 (U.S. 2017).
Opinion
Motion of Apotex, Inc., et al. for leave to file a brief as amici curiae granted. Petition for writ of certiorari to the United States Court of Appeals for the Federal Circuit granted. The case is consolidated and a total of one hour is allotted for oral argument.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Amgen Inc. v. Sandoz Inc.
877 F.3d 1315 (Federal Circuit, 2017)
Cite This Page — Counsel Stack
Bluebook (online)
137 S. Ct. 808, 196 L. Ed. 2d 594, 85 U.S.L.W. 3343, 2017 WL 125661, 2017 U.S. LEXIS 692, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sandoz-inc-v-amgen-inc-scotus-2017.